Renal Cancer - Results from #140

Effectiveness of Second-Line Cabozantinib in Metastatic Clear Cell Renal Cell Carcinoma Patients After First-Line Treatment with Immune Checkpoint Inhibitor-based Combinations. September 13, 2024

Differences in mutations across tumour sizes in clear-cell renal cell carcinoma. September 13, 2024

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. September 13, 2024

Approach to Diagnosis of TFE3-rearranged Renal Cell Carcinoma in a Limited Resource Setting: A Case Report. September 12, 2024

First-line Systemic Therapy Following Adjuvant Immunotherapy in Renal Cell Carcinoma: An International Multicenter Study. September 12, 2024

Diagnostic accuracy and safety of renal tumour biopsy in patients with small renal masses and its impact on treatment decisions. September 12, 2024

Abscopal effect following checkpoint inhibitor therapy and localized radiotherapy for metastatic clear cell renal cell carcinoma: A case report. September 11, 2024

Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis. September 11, 2024

Comparing open and robot-assisted partial nephrectomy - a single institution report. September 11, 2024

Durable Local Control With Preserved Renal Function for Stereotactic Body Radiotherapy in Cryoablation-Refractory Clear Cell Renal Carcinoma. September 10, 2024

Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de-differentiation (ARON-1 study). September 10, 2024

Effects of a Remote Multimodal Psychoeducational Intervention Nursing Program on Mental Health and Quality of Life of Renal Cell Carcinoma Survivors: A Retrospective Study. September 9, 2024

Immunotherapeutic Innovations in Clear Cell Renal Cell Carcinoma: Current Strategies and Future Directions. September 9, 2024

Quadratus lumborum block for procedural and postprocedural analgesia in renal cell carcinoma percutaneous cryoablation. September 6, 2024

Epigenetic modification of Castor zinc finger 1 (CASZ1) is associated with tumor microenvironments and prognosis of clear cell renal cell carcinoma. September 6, 2024

Clinical Outcomes for Metastatic Renal Cell Carcinoma (mRCC) Patients Ineligible for Front-line Clinical Trials. September 5, 2024

Phase II Trial of Intermittent Therapy in Patients with Metastatic Renal Cell Carcinoma Treated with Front-line Ipilimumab and Nivolumab. September 5, 2024

Randomized phase 2 dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma. September 5, 2024

Renal cell carcinoma: entering the age of biomarkers. September 4, 2024

Prognostic Role of Pre-Treatment Body Composition Parameters in Patients Undergoing First-Line Immunotherapy for Metastatic Renal Cell Carcinoma. September 4, 2024

Page 8 of 455